<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wiki.docmoates.com/index.php?action=history&amp;feed=atom&amp;title=Verapamil</id>
	<title>Verapamil - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.docmoates.com/index.php?action=history&amp;feed=atom&amp;title=Verapamil"/>
	<link rel="alternate" type="text/html" href="https://wiki.docmoates.com/index.php?title=Verapamil&amp;action=history"/>
	<updated>2026-06-17T15:49:57Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.42.4</generator>
	<entry>
		<id>https://wiki.docmoates.com/index.php?title=Verapamil&amp;diff=4032&amp;oldid=prev</id>
		<title>Docmoates: NCLEX nursing pharmacology monographs — batch import</title>
		<link rel="alternate" type="text/html" href="https://wiki.docmoates.com/index.php?title=Verapamil&amp;diff=4032&amp;oldid=prev"/>
		<updated>2026-06-17T13:37:26Z</updated>

		<summary type="html">&lt;p&gt;NCLEX nursing pharmacology monographs — batch import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;&amp;quot;&amp;gt;&lt;br /&gt;
&amp;#039;&amp;#039;Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and &amp;#039;&amp;#039;&amp;#039;must be verified against current manufacturer labeling before clinical use&amp;#039;&amp;#039;&amp;#039;. This is educational content, not prescribing guidance.&amp;#039;&amp;#039;&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Verapamil&amp;#039;&amp;#039;&amp;#039; (brand name Calan) &amp;amp;mdash; Antihypertensive, antianginal, antiarrhythmic; Non-dihydropyridine calcium channel blocker.&lt;br /&gt;
&lt;br /&gt;
== Identification ==&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Therapeutic class:&amp;#039;&amp;#039;&amp;#039; Antihypertensive, antianginal, antiarrhythmic.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Pharmacologic class:&amp;#039;&amp;#039;&amp;#039; Non-dihydropyridine calcium channel blocker.&lt;br /&gt;
&lt;br /&gt;
== Pharmacology ==&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Mechanism of action:&amp;#039;&amp;#039;&amp;#039; Strongest cardiac-selective calcium blocker; slows AV node conduction and heart rate, with vasodilation.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Onset / peak / duration:&amp;#039;&amp;#039;&amp;#039; PO onset 1 to 2 hours; IV within minutes; ER lasts 24 hours.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Half-life / therapeutic level:&amp;#039;&amp;#039;&amp;#039; Half-life 3 to 7 hours; no routine level.&lt;br /&gt;
&lt;br /&gt;
== Clinical use ==&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Indications:&amp;#039;&amp;#039;&amp;#039; Hypertension, angina, supraventricular arrhythmias, rate control.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Usual dose, route, frequency:&amp;#039;&amp;#039;&amp;#039; 180 to 480 mg PO daily; IV for acute SVT.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Maximum dose / adjustments:&amp;#039;&amp;#039;&amp;#039; Max about 480 mg/day; reduce in hepatic impairment; pronounced constipation risk in elderly.&lt;br /&gt;
&lt;br /&gt;
== Safety ==&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Contraindications:&amp;#039;&amp;#039;&amp;#039; Severe left ventricular dysfunction, heart block, sick sinus syndrome, hypotension, with IV beta blockers.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Black box warning:&amp;#039;&amp;#039;&amp;#039; None.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Interactions:&amp;#039;&amp;#039;&amp;#039; Beta blockers (bradycardia, block), digoxin (raises levels), statins, grapefruit (food).&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Pregnancy / lactation:&amp;#039;&amp;#039;&amp;#039; Use only if clearly needed.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;High-alert:&amp;#039;&amp;#039;&amp;#039; IV form warrants extra caution.&lt;br /&gt;
&lt;br /&gt;
== Adverse effects ==&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Common side effects:&amp;#039;&amp;#039;&amp;#039; Constipation (prominent), bradycardia, edema, dizziness.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Serious effects to report:&amp;#039;&amp;#039;&amp;#039; Heart block, severe bradycardia, worsening heart failure.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Antidote / reversal:&amp;#039;&amp;#039;&amp;#039; Calcium, atropine, supportive care.&lt;br /&gt;
&lt;br /&gt;
== Nursing process ==&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Assessment before administration:&amp;#039;&amp;#039;&amp;#039; Heart rate, blood pressure, ECG, bowel pattern.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Interventions during therapy:&amp;#039;&amp;#039;&amp;#039; Encourage fiber and fluids for constipation; hold for bradycardia.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Monitor:&amp;#039;&amp;#039;&amp;#039; Heart rate, blood pressure, ECG, bowel function.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Evaluation / expected outcome:&amp;#039;&amp;#039;&amp;#039; Rate and blood pressure control.&lt;br /&gt;
&lt;br /&gt;
== Patient teaching ==&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Patient teaching:&amp;#039;&amp;#039;&amp;#039; Manage constipation with fiber and fluids.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Notify provider if:&amp;#039;&amp;#039;&amp;#039; Slow heartbeat, fainting, severe constipation, shortness of breath.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Administration tips:&amp;#039;&amp;#039;&amp;#039; Swallow ER whole; avoid grapefruit.&lt;br /&gt;
&lt;br /&gt;
[[Category:Calcium Channel Blockers]]&lt;/div&gt;</summary>
		<author><name>Docmoates</name></author>
	</entry>
</feed>